New weight-loss drugs are driving up costs for Pennsylvanias Medicaid program, officials told legislators this week, likely leading to more than $1 billion in new costs this year
TGA issues warning over GLP-1-based drugs' potential to cause rare eye disorder Fri 24 Jul 2026 at 11:13am In short: The Therapeutic Goods Administration is warning of a rare but serious eye disorder that could be caused by GLP-1-based drugs
However, in most trials, participants received metformin, either as monotherapy or in combination with other agents, except for three trials where participants received no background glucose-lowering therapy after randomisation [26, 40, 49]
In addition to significant weight loss, Semaglutide can also lead to lower blood sugar levels, improved cardiovascular risk factors, as well as a suppressed appetite, enhanced insulin secretion, and reduced glucagon levels